Michigan Prior Authorization Request Form
For Prescription Drugs

Instructions

Important: Please read all instructions below before completing FIS 2288.

Section 2212c of Public Act 218 of 1956, MCL 500.2212c, requires the use of a standard prior authorization form when a policy, certificate or contract requires prior authorization for prescription drug benefits.

A standard form, FIS 2288, is being made available to simplify exchanges of information between prescribers and health insurers as part of the process of requesting prescription drug prior authorization. This form will be updated periodically and the form number and most recent revision date are displayed in the top left hand corner.

➢ Prior authorization requests are defined as requests for pre-approval from an insurer for specified medications or quantities of medications before they are dispensed.
➢ Prescriber means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
➢ Prescription drug means the term as defined in section 17708 of the Public Health Code, 1978 PA 368, MCL 333.17708.
➢ This form is made available for use by prescribers to initiate a prior authorization request.
➢ Insurers may request additional information or clarification needed to process a prior authorization request. The prior authorization is not considered granted if the prescriber fails to submit the additional information within 72 hours after the date and time of the original submission of a properly completed prior authorization request.
➢ In order to designate a prior authorization request for expedited review, a prescriber must certify that applying the 15-day standard review period may seriously jeopardize the life and health of the patient or the patient’s ability to regain maximum function.
Michigan Prior Authorization
Request Form for Prescription Drugs   Fax: 858-790-7100

☐ Expedited Review Request: I hereby certify that a standard review period may seriously jeopardize the life or health of the patient or the patient’s ability to regain maximum function.
Physician’s Direct Contact Phone Number (   ) ______-_________  Initials: ________________

A) Reason for Request
☐ Initial Authorization Request   ☐ Renewal Request   ☐ DAW

B) Patient Demographics
Is patient hospitalized: ☐ Yes ☐ No
Patient Name: ___________________________________  DOB: ____________________
Patient Health Plan ID: ______________________________________________________
☐ Male   ☐ Female

C) Pharmacy Insurance Plan
☐ Priority  ☐ Magellan   ☐ Blue Cross Blue Shield of Michigan  ☐ HAP  ☐ ________________
☐ Total Health Care  ☐ Blue Care Network  ☐ HealthPlus of Michigan  ☐ Meridian Health Plan

D) Prescriber Information
Prescriber Name: ____________________________  NPI: ____________________  Specialty: ________________
DEA (required for controlled substance requests only): ____________________________
Contact Name: ____________________________  Contact Phone: ________________  Contact Fax: ______________________
Health Plan Provider ID (if accessible): _______________________________________

E) Pharmacy Information (optional)
Pharmacy Name______________________________  Pharmacy Telephone________________________

F) Requested Prescription Drug Information
Drug Name: ___________________________________________  Strength: ________________
Dosing Schedule: ____________________________  Duration: ____________________________
Diagnosis (specific) with ICD#: ____________________________
Place of infusion / injection (if applicable): __________________________________________
Facility Provider ID / NPI: ____________________________
Has the patient already started the medication? ______ Yes ______ No  If so, when? ___________
G) Rationale for Prior Authorization (e.g., information such as history of present illness, past medical history, current medications, etc.; you may also attach chart notes to support your request if you believe they will assist with the review process)

H) Failed/Contraindicated Therapies

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Strength</th>
<th>Dosing Schedule</th>
<th>Duration</th>
<th>Adverse Event/Specific Failure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

I) Other Pertinent Information (Optional - to be filled out if other information is necessary such as relevant diagnostic labs, measures of response to treatment, etc.) Please refer to plan's website for additional information that may be necessary for review. Please note that sending this form with insufficient clinical information may result in extended review period or adverse determination.

I represent to the best of my knowledge and belief that the information provided is true, complete and fully disclosed. A person may be committing insurance fraud if false or deceptive information with the intent to defraud is provided.

Physician's Name: __________________________________________

Physician's Signature: ______________________________________

Date: ______________

PA 218 of 1956 as amended requires the use of a standard prior authorization form by prescribers when a patient's health plan requires prior authorization for prescription drug benefits.

*For Health Plan Use Only*

<table>
<thead>
<tr>
<th>Request Date:</th>
<th>LOB:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved:</td>
<td>Denied:</td>
</tr>
<tr>
<td>Approved By:</td>
<td>Denied By:</td>
</tr>
<tr>
<td>Effective Date:</td>
<td>Reason for Denial:</td>
</tr>
<tr>
<td>Additional Comments:</td>
<td></td>
</tr>
</tbody>
</table>

Michigan Department of Insurance and Financial Services

DIFS is an equal opportunity employer/program. Auxiliary aids, services and other reasonable accommodations are available upon request to individuals with disabilities.

Visit DIFS online at: www.michigan.gov/difs Phone DIFS toll-free at: 877-999-6442
UNIVERSITY OF MICHIGAN – ZELBORAF (vemurafenib)

Some of the information needed to make a determination for coverage is not specifically requested on the Michigan Prior Authorization Request Form for Prescription Drugs. To avoid delays in reviewing your request, please make sure to include all of the following information.

<table>
<thead>
<tr>
<th>Answer questions 1 through 7 for your patient</th>
<th>Y</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Is the patient age 18 years or older?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Does the patient have unresectable or metastatic melanoma with BRAF&lt;sup&gt;V600E&lt;/sup&gt; mutation that has been as detected by an FDA-approved test?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Will the patient be monitored for cutaneous squamous cell carcinoma (cuSCC) and receive dermatologic evaluation prior to initiation of Zelboraf treatment, every 2 months during treatment, and 6 months after treatment is discontinued?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Will the patient be monitored before initiation, and regularly during treatment with Zelboraf, for other dermatologic reactions including new primary malignant melanoma, hypersensitivity reactions, ophthalmologic reactions (e.g., uveitis) and liver laboratory abnormalities?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Will the patient’s ECG and electrolytes be monitored before treatment, after dose modification, and regularly during treatment with Zelboraf&lt;sup&gt;a&lt;/sup&gt;?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Will the patient be advised to check their skin regularly during treatment and up to 6 months after discontinuation, and instructed to avoid sun exposure while taking Zelboraf, wear protective clothing, and use a broad spectrum UVA/UVB sunscreen and lip balm (SPF≥30) when outdoors to help protect against sunburn?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. If the patient is male or female of childbearing potential, will the patient be apprised of the potential for Zelboraf to cause fetal harm and be advised to use appropriate contraceptive measures during treatment with Zelboraf and for at least 2 months after its discontinuation?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Effective June 1, 2016